Cohort Core
队列核心
基本信息
- 批准号:10327460
- 负责人:
- 金额:$ 18.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-13 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AgingCOVID-19CardiacCardiovascular DiseasesClassificationClinicalClinical TrialsCohort StudiesCollaborationsCommunitiesComplexCoupledDataData PoolingData SetDevelopmentDevicesDiseaseEFRACElectronic Health RecordEnvironmental ExposureFunctional disorderFundingGenetic DeterminismGenomeGenomicsGoalsGrantHeartHeart failureHeterogeneityHistologicHuman Genome ProjectImageInvestigationLaboratory FindingMachine LearningModalityMolecularMolecular TargetMultiomic DataNational Heart, Lung, and Blood InstitutePaperPathway interactionsPharmaceutical PreparationsPhenotypePhysiologicalProteomicsPublishingRandomized Clinical TrialsReportingRequest for ApplicationsResearchResearch PriorityResistanceResourcesStructureSyndromeSystems BiologyTechniquesTrans-Omics for Precision MedicineTranslationsUnited States National Academy of SciencesVisionWorkcohortcollaborative trialdata managementdisease classificationdiverse dataexercise capacityexperiencegenome wide association studygenome-widegenomic epidemiologyheart imagingimprovedinnovationinsightmembermetabolomicsmultidimensional datamultiple omicsnovelnovel strategiespatient subsetsprecision medicinepreservationprospectivesocioeconomicsworking group
项目摘要
PROJECT SUMMARY
Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous, multifaceted syndrome that
is an ideal setting for the application of precision medicine. HFpEF has proven resistant to conventional
techniques for the study of its underlying pathophysiology and conduct of randomized clinical trials. New
approaches are therefore desperately needed, as indicated in a recently published white paper which
summarized the deliberations of the NHLBI Working Group on Research Priorities in HFpEF. The National
Academy of Sciences Precision Medicine Report proposes that “when multiple molecular indicators are used in
combination with conventional clinical, histological, and laboratory findings, they offer the opportunity for a more
accurate and precise description and classification of disease”. This paradigm is also supported by the NHLBI’s
Strategic Vision, which argues that a combination of omics (e.g., genomics, proteomics, and metabolomics),
coupled with clinical and physiological data, will be necessary to advance understanding of the pathobiological
basis of complex clinical syndromes such as HFpEF, and provides the underlying rationale for HeartShare.
The promise of precision medicine lies in data diversity. More than the sheer size of biomedical data, it is the
layering of multiple data modalities, offering complementary perspectives, that will enable the identification of
patient subgroups with shared pathophysiology. HeartShare provides an immense opportunity to conduct a multi-
layered precision medicine investigation of HFpEF. The HeartShare Cohort Core will create a lasting impact on
the HFpEF field by accomplishing the following specific aims, which are responsive to the HeartShare request
for applications. (1) To pool, clean, and harmonize all data and images from multiple cardiovascular disease
cohorts and HF trials in order to develop a comprehensive, data-rich resource for the research community to
identify novel HFpEF subtypes. (2) To combine machine learning and multi-omics analyses using a hypothesis-
driven approach by interrogating previously identified HFpEF subtypes in order to improve the identification and
molecular/pathophysiologic understanding of these HFpEF subtypes. (3) To combine machine learning and
multi-dimensional data (including multi-omics) using unbiased approaches to identify and validate novel HFpEF
subtypes.
项目摘要
射血分数正常的心力衰竭(HF)是一种异质性、多方面的综合征,
是精准医疗应用的理想场所。HFpEF已被证明对传统的
研究其潜在的病理生理学和进行随机临床试验的技术。新
因此,正如最近发表的一篇白色论文所指出的,
总结了NHLBI HFpEF研究优先事项工作组的审议情况。国家
科学院精准医学报告提出,“当多个分子指标用于
结合常规的临床、组织学和实验室检查结果,它们提供了更多的机会,
准确和精确的疾病描述和分类”。这一范例也得到了NHLBI的支持,
战略愿景,它认为,一个组合的组学(例如,基因组学、蛋白质组学和代谢组学),
再加上临床和生理数据,将是必要的,以促进了解的病理生物学
HFpEF等复杂临床综合征的基础,并提供了HeartShare的基本原理。
精准医疗的前景在于数据的多样性。不仅仅是生物医学数据的庞大规模,
多种数据模式的分层,提供互补的视角,这将有助于确定
具有共同病理生理学的患者亚组。HeartShare提供了一个巨大的机会来进行多-
HFpEF的分层精准医学研究。HeartShare队列核心将产生持久的影响,
通过完成以下响应于HeartShare请求的特定目标来控制HFpEF字段
用于应用程序。(1)汇集、清理和协调来自多种心血管疾病的所有数据和图像
队列和HF试验,以便为研究界开发全面的,数据丰富的资源,
鉴定新HFpEF亚型。(2)使用假设将联合收割机和多组学分析结合起来-
通过询问先前鉴定的HFpEF亚型来驱动方法,以提高鉴定和
这些HFpEF亚型的分子/病理生理学理解。(3)为了将联合收割机和
多维数据(包括多组学),使用无偏方法识别和验证新型HFpEF
亚型
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sanjiv J Shah其他文献
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbAsub1c/sub levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
司美格鲁肽在射血分数保留的肥胖相关心力衰竭和 2 型糖尿病患者中(无论基线糖化血红蛋白水平如何)(STEP-HFpEF DM):一项随机、安慰剂对照试验中心力衰竭和代谢结局的预先指定分析
- DOI:
10.1016/s2213-8587(24)00304-8 - 发表时间:
2025-03-01 - 期刊:
- 影响因子:41.800
- 作者:
Melanie J Davies;Peter van der Meer;Subodh Verma;Shachi Patel;Khaja M Chinnakondepalli;Barry A Borlaug;Javed Butler;Dalane W Kitzman;Sanjiv J Shah;Signe Harring;Afshin Salsali;Søren Rasmussen;Dirk von Lewinski;Walter Abhayaratna;Mark C Petrie;Mikhail N Kosiborod;STEP-HFpEF Trials Committees and Investigators - 通讯作者:
STEP-HFpEF Trials Committees and Investigators
210 - Once-weekly semaglutide in heart failure with preserved ejection fraction and obesity: main results from the STEP-HFpEF trial
- DOI:
10.1016/j.orcp.2024.09.084 - 发表时间:
2024-09-01 - 期刊:
- 影响因子:
- 作者:
Andrew Sindone;Mikhail Kosiborod;Steen Z Abildstrøm;Barry A Borlaug;Javed Butler;Søren Rasmussen;Melanie J Davies;G. Kees Hovingh;Dalane W Kitzman;Marie L Lindegaard;Daniél Vega Møller;Sanjiv J Shah;Marianne Bach Treppendahl;Subodh Verma;Mark C Petrie - 通讯作者:
Mark C Petrie
211 - Once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes: main results from the STEP-HFpEF DM trial
- DOI:
10.1016/j.orcp.2024.09.085 - 发表时间:
2024-09-01 - 期刊:
- 影响因子:
- 作者:
Andrew Sindone;Mikhail Kosiborod;Mark C Petrie;Barry A Borlaug;Javed Butler;Melanie J Davies;G. Kees Hovingh;Dalane W Kitzman;Daniél Vega Møller;Marianne Bach Treppendahl;Subodh Verma;Thomas J Jensen;Karoline Liisberg;Marie L Lindegaard;Sanjiv J Shah - 通讯作者:
Sanjiv J Shah
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
非奈利酮与心力衰竭中新发糖尿病:FINEARTS-HF 试验的预先指定分析
- DOI:
10.1016/s2213-8587(24)00309-7 - 发表时间:
2025-02-01 - 期刊:
- 影响因子:41.800
- 作者:
Jawad H Butt;Pardeep S Jhund;Alasdair D Henderson;Brian L Claggett;Akshay S Desai;Prabhakar Viswanathan;Peter Kolkhof;Patrick Schloemer;Flaviana Amarante;Carolyn S P Lam;Michele Senni;Sanjiv J Shah;Adriaan A Voors;Faiez Zannad;Bertram Pitt;Muthiah Vaduganathan;Scott D Solomon;John J V McMurray;FINEARTS-HF Committees and Investigators - 通讯作者:
FINEARTS-HF Committees and Investigators
Sanjiv J Shah的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sanjiv J Shah', 18)}}的其他基金
相似国自然基金
CEACAM5调控Galectin-9介导的CD4+T细胞极化在COVID-19肠屏障损伤的作用机制研究
- 批准号:82370569
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
COVID-19疫情对我国儿童生长发育影响的异质性研究
- 批准号:42371429
- 批准年份:2023
- 资助金额:52.00 万元
- 项目类别:面上项目
传染病模型的稳态切换过程研究及其在治疗COVID-19中的应用
- 批准号:LQ23A010016
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
“湿漫膜原”视角下研究加味达原饮重塑COVID-19“免疫炎症稳态”的分子机制:TLR4介导IRF3/NF-κB通路串扰
- 批准号:82374291
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
COVID-19中线粒体囊泡抑制CD8+T细胞记忆分化的机制研究
- 批准号:82300018
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
COVID-19疫情爆发后武汉地区儿童副流感病毒3型的流行趋势和进化规律研究
- 批准号:n/a
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于 GDF15-IL6 信号轴探究扶正解毒方逆转血管内皮衰老治疗COVID-19的作用与机制
- 批准号:82374392
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
多维不平稳和长记忆性的复杂整值时间序列的建模及其在Covid-19研究中的应用
- 批准号:12301358
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
COVID-19疫苗同源、异源加强剂次细胞免疫与体液免疫效应的前瞻性队列研究
- 批准号:n/a
- 批准年份:2023
- 资助金额:10.0 万元
- 项目类别:省市级项目
基于人源细胞3D培养和精密肺切片技术探讨慢阻肺患者COVID-19易感机制研究
- 批准号:LY23H190003
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
The Use of Human Cardiac Organoids to Model COVID-19 Cytokine Storm Induced Cardiac Injury
使用人类心脏类器官模拟 COVID-19 细胞因子风暴诱发的心脏损伤
- 批准号:
10464114 - 财政年份:2022
- 资助金额:
$ 18.81万 - 项目类别:
Immunologic basis of cardiac disease after severe COVID-19
重症COVID-19后心脏病的免疫学基础
- 批准号:
10442251 - 财政年份:2022
- 资助金额:
$ 18.81万 - 项目类别:
Exploratory analysis for prognosis prediction methods using cardiac biomarkers in patients with coronavirus disease 2019 (COVID-19)
使用心脏生物标志物对 2019 年冠状病毒病(COVID-19)患者的预后预测方法进行探索性分析
- 批准号:
22K16124 - 财政年份:2022
- 资助金额:
$ 18.81万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Immunologic basis of cardiac disease after severe COVID-19
重症COVID-19后心脏病的免疫学基础
- 批准号:
10650182 - 财政年份:2022
- 资助金额:
$ 18.81万 - 项目类别:
The Use of Human Cardiac Organoids to Model COVID-19 Cytokine Storm Induced Cardiac Injury
使用人类心脏类器官模拟 COVID-19 细胞因子风暴诱发的心脏损伤
- 批准号:
10733416 - 财政年份:2022
- 资助金额:
$ 18.81万 - 项目类别:
Investigating the Cardiac and Brain Impact of COVID-19 in Diverse Populations
调查 COVID-19 对不同人群的心脏和大脑影响
- 批准号:
473326 - 财政年份:2022
- 资助金额:
$ 18.81万 - 项目类别:
Operating Grants
The BEACONS Platform - Comprehensive biomarker analysis for prediction of clinical course and management in acute coagulopathy in sepsis, trauma, cardiac arrest, and COVID-19
BEACONS 平台 - 综合生物标志物分析,用于预测脓毒症、创伤、心脏骤停和 COVID-19 急性凝血病的临床病程和管理
- 批准号:
454967 - 财政年份:2021
- 资助金额:
$ 18.81万 - 项目类别:
Fellowship Programs
Cardiac Magnetic Resonance for Tissue Characterization Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors
心脏磁共振对 COVID-19 幸存者心肺症状、努力耐受力和预后的基于组织特征的风险分层
- 批准号:
10673997 - 财政年份:2021
- 资助金额:
$ 18.81万 - 项目类别:
Systematic implementation and impact evaluation of data-driven cardiac surgery triaging tools to optimize operational efficiency and enhance patient outcomes during the COVID-19 pandemic and beyond
数据驱动的心脏手术分诊工具的系统实施和影响评估,以优化运营效率并提高 COVID-19 大流行期间及之后的患者治疗效果
- 批准号:
460227 - 财政年份:2021
- 资助金额:
$ 18.81万 - 项目类别:
Operating Grants
The indirect impact of COVID-19 on cardiac function and associated outcomes in patients awaiting cardiac surgery: An opportunity to inform data-driven surgical wait list management
COVID-19 对等待心脏手术患者的心功能和相关结果的间接影响:为数据驱动的手术候补名单管理提供信息的机会
- 批准号:
460229 - 财政年份:2021
- 资助金额:
$ 18.81万 - 项目类别:
Operating Grants